Your browser doesn't support javascript.
loading
Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study.
Ahmadi, Khadijeh; Farasat, Alireza; Rostamian, Mosayeb; Johari, Behrooz; Madanchi, Hamid.
Affiliation
  • Ahmadi K; Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
  • Farasat A; Cellular and Molecular Research Center, Research Institute for Prevention of Non Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Rostamian M; Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Johari B; Infectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Madanchi H; Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
J Biomol Struct Dyn ; 40(12): 5566-5576, 2022 08.
Article in En | MEDLINE | ID: mdl-33438525
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Repositioning / Enfuvirtide / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Clinical_trials Limits: Humans Language: En Journal: J Biomol Struct Dyn Year: 2022 Document type: Article Affiliation country: Iran Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Repositioning / Enfuvirtide / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Clinical_trials Limits: Humans Language: En Journal: J Biomol Struct Dyn Year: 2022 Document type: Article Affiliation country: Iran Country of publication: United kingdom